A man in the UK with a diagnosis of ADHD is, on average, dying earlier than a man without one. So is a woman. The gap is not small. It is not a statistical curiosity. It is, in the careful estimates of a January 2025 study published in The British Journal of Psychiatry, somewhere between 4.5 and 9 years for men and between 6.5 and 11 years for women. The study is the largest of its kind ever conducted, drawing on the primary care records of more than 330,000 adults in the UK National Health Service. The finding is sobering. The interpretation matters.

The study was led by Dr. Liz O’Nions, an honorary research fellow at University College London, and senior author Professor Josh Stott of UCL’s Psychology and Language Sciences department. The team examined anonymized primary care data from 30,029 adults across the UK who had received a formal ADHD diagnosis, comparing them to 300,390 adults without ADHD who were matched on age, sex, and primary care practice. The matching is what gives the comparison its weight. The two groups differed in their ADHD status; on every other major demographic, they were the same.

What the researchers found, across nearly two decades of follow-up data from 2000 to 2019, was a consistent pattern of higher mortality among the adults with ADHD diagnoses. Men with ADHD faced a mortality rate roughly 1.89 times that of matched controls. For women, the multiplier was even higher at 2.13. The pattern held across all age groups examined. It produced the years-of-life-lost estimates that have, in the months since publication, drawn international attention and sober analysis from the broader ADHD research community.

“It is deeply concerning that some adults with diagnosed ADHD are living shorter lives than they should,” Stott said in a UCL statement accompanying the paper. “People with ADHD have many strengths and can thrive with the right support and treatment. However, they often lack support and are more likely to experience stressful life events and social exclusion, negatively impacting their health and self-esteem.”

Lead author O’Nions added: “Although many people with ADHD live long and healthy lives, our finding that on average they are living shorter lives than they should indicates unmet support needs. It is crucial that we find out the reasons behind premature deaths so we can develop strategies to prevent these in the future.”

This article is not an alarm. It is an attempt to take the finding seriously without misreading it. The data is real. The mechanism is not what most readers will assume. And what the researchers are pointing to is something more practical, and more changeable, than the headline number suggests.

What the Study Did

The methodology is worth understanding because it shapes what the finding does and does not say.

The researchers used the IQVIA Medical Research Database, a large anonymized collection of UK primary care records covering millions of patients. From this, they identified 30,029 adults who had received an ADHD diagnosis recorded in their primary care file at some point during the study window. Each of these adults was matched to ten adults without an ADHD diagnosis, drawn from the same primary care practices, of the same age band and sex. This produced a comparison group of 300,390 controls, giving the study its statistical power.

The outcome of interest was straightforward: death. The researchers tracked which patients died during the follow-up period from any cause, and used standard actuarial methods to estimate the life expectancy gap implied by the differential mortality. The point estimates were 6.78 years lost for men and 8.64 years lost for women, with confidence intervals running from 4.5 to 9 years for men and 6.5 to 11 years for women. The wide intervals reflect the difficulty of estimating life expectancy from a finite follow-up window in adults who have not yet completed their lives.

The matched design is what makes the comparison strong. By matching on age, sex, and primary care practice, the researchers controlled for the most obvious confounders: people of the same age, same sex, in the same geographic area, with access to the same healthcare system. The remaining difference between groups was their ADHD diagnosis status, plus whatever clusters with that status in the real population.

The study also documents that adults with ADHD in the sample had elevated baseline rates of multiple co-occurring conditions. Anxiety, depression, substance use disorders, autism, learning disabilities, and certain physical health conditions all appeared at higher frequencies in the ADHD group than in the matched controls. These comorbidities are part of the picture the researchers were measuring, not noise to be removed from it.

What the Mechanism Looks Like

The mortality gap is real. The question of why it exists is where the article gets careful.

The researchers are explicit that they do not believe ADHD itself, in any direct biological sense, is shortening lives. ADHD is a neurodevelopmental condition that affects attention, impulsivity, and emotional regulation. It is not, by itself, a cause of cardiovascular disease, cancer, or any of the other leading causes of death in middle and later adulthood. What ADHD does is shape the conditions of a person’s life over decades, and those conditions are what produce the mortality gap.

The mechanism, as O’Nions, Stott, and their team describe it, has several interlocking components.

First, adults with diagnosed ADHD have higher rates of co-occurring mental health conditions. Depression, anxiety, substance use disorders, and other mental health diagnoses cluster with ADHD at rates well above the general population. Each of these conditions carries its own mortality risk, and they compound. A person navigating ADHD plus depression plus a substance use disorder is at considerably higher risk than a person navigating any one of these alone.

Second, adults with ADHD experience higher rates of social and economic adversity. Studies have consistently documented higher rates of unemployment, financial hardship, relationship instability, and social exclusion in adults with ADHD. These adversities have well-documented effects on physical health. Chronic financial stress is associated with cardiovascular disease, immune dysfunction, and earlier mortality across all populations, not just people with ADHD. ADHD does not cause heart disease, but the cumulative stress of an ADHD-shaped working life can.

Third, health behaviors track with ADHD in ways that affect long-term mortality. Research summarized in NPR’s coverage of the study identified the strongest predictors of shorter life expectancy in adults with ADHD as lower incomes, higher rates of smoking, less exercise, poorer nutrition, and risky driving. Each of these is downstream of executive function challenges and the social conditions that surround them. A person whose brain struggles to plan, follow through, and regulate impulses is operating against a current when it comes to the everyday habits that protect long-term health.

Fourth, and perhaps most consequential, the healthcare system has not been built for adults with ADHD. Healthcare itself requires substantial executive function: scheduling appointments, refilling prescriptions, following up on test results, navigating insurance, asking the right questions, advocating when a problem is not being taken seriously. Adults with ADHD struggle with each of these. Their health needs go unmet not because the medical care does not exist but because the cognitive overhead of accessing care exceeds what the disorder allows. The chronic conditions that would have been caught and treated in a different person go untreated. The early warning signs that would have prompted a doctor’s visit get missed.

The aggregate effect of these mechanisms is the mortality gap. The gap is not ADHD killing people directly. It is the cumulative weight of a life lived without the supports that would offset the practical challenges of executive function differences, in a healthcare system that does not accommodate them, and in a social and economic environment that punishes them.

The Larger Risk Picture

Russell Barkley, the retired Virginia Commonwealth University psychiatry professor whose decades of work on ADHD make him one of the field’s most cited researchers, was asked by NPR for his reaction to the O’Nions study.

“It’s a very important article,” Barkley said.

The endorsement is consequential. Barkley’s own 2019 study, using a different methodology and a different population, reached strikingly similar conclusions. Barkley followed a cohort of children diagnosed with ADHD into adulthood and used estimated life expectancy modeling to project the consequences of the lifestyle and health profile he observed. His estimate was a life expectancy reduction of approximately 8.4 years for adults whose childhood ADHD persisted into adulthood, with additional years of unhealthy living layered on top.

Two studies, conducted independently, on different populations, using different methodologies, converged on similar conclusions. That convergence is the strongest signal in the data. A single dramatic finding can always be a methodological artifact. Two findings reaching the same place through different paths are harder to dismiss.

Both researchers emphasize a critical point: the gap is not produced by ADHD as a disease entity but by the lifestyle, mental health, and social adversity factors that cluster with the condition under current systems of care. The implication is that the gap is, in principle, modifiable. A health system designed to meet adults with ADHD where they are, with adequate mental health support, accessible primary care, and appropriate accommodation of executive function differences, would not produce the same mortality differential.

The implication runs in both directions. If the gap is produced by inadequate systems rather than by the disorder itself, then closing the gap is a question of system design rather than of biological intervention. It is, in that sense, a more hopeful finding than the headline number suggests. The years of life being lost are not lost to an immovable biological fact. They are being lost to choices that systems and policymakers are currently making, and could be making differently.

The Underdiagnosis Problem

The study has one limitation that the researchers flag carefully and that readers should take seriously. The data captures adults with diagnosed ADHD. It does not capture adults with ADHD who have not been diagnosed.

This is not a small omission. The same paper notes that most UK adults with ADHD characteristics are undiagnosed and not receiving treatment. The global prevalence of adult ADHD is estimated at roughly 2.8 percent based on multinational surveys. The UK adult diagnostic rate is substantially lower than that. Most people who would meet the diagnostic criteria are not in the dataset being studied here, because they have never been identified by the healthcare system.

This produces an interpretive complication. Adults who get formally diagnosed with ADHD as adults tend to be people whose lives have arrived at a point where the diagnosis becomes necessary, often after struggles severe enough to drive them into the healthcare system in the first place. Adults who navigate undiagnosed ADHD without ever seeking formal evaluation may, on average, be doing better in some practical sense, or they may be doing worse and simply not appearing in the data. The study cannot distinguish between these possibilities.

What the study can say is that within the population of adults who have been diagnosed with ADHD, mortality is elevated. What it cannot say is whether the millions of adults with undiagnosed ADHD share the same elevated mortality, lower mortality, or higher mortality than the diagnosed group. Each of these is plausible, and each tells a different story about what the disorder does to a population over decades. Settling the question will require studies that capture undiagnosed ADHD through retrospective screening or other methods, and those studies are harder to do.

The implication for readers with ADHD or with family members with ADHD is that the headline numbers should be treated with appropriate caution. They describe an average across a particular diagnosed population. They do not describe any individual’s destiny. A person with ADHD who has good mental health support, stable employment, healthy relationships, and consistent access to healthcare is not facing the headline mortality risk. The risk is concentrated in the population whose ADHD has come with the cluster of social, economic, and mental health adversities the study documents.

The Sex Difference

One of the more striking findings in the study is that the mortality gap is larger for women than for men. Women with diagnosed ADHD lose more years of life expectancy than men do.

This is consistent with a pattern that ADHD researchers have been documenting for years: the consequences of adult ADHD tend to be worse for women than for men, despite ADHD being more frequently diagnosed in men. The cause is most likely the same cause that explains the female underdiagnosis in childhood. Girls and women with ADHD are more likely to present with inattentive symptoms, which produce internal struggles rather than external behaviors. Their ADHD is less likely to be identified in childhood. When it is finally identified in adulthood, it has typically been joined by years of anxiety, depression, eating disorders, and the cumulative damage of struggle that the system did not name correctly.

By the time a woman is being formally diagnosed with ADHD in adulthood, she has often spent decades operating with executive function challenges, being told by herself and others that the struggle is a character flaw rather than a treatable condition, and managing the mental health consequences of that misattribution. The mortality data is, in this reading, the long-term cost of that history.

The larger female gap also reflects, the researchers suggest, the particular intersection of ADHD with women’s social and economic outcomes. Women with ADHD are more likely than men with ADHD to be primary caregivers managing the executive demands of running a household, navigating their own care and others’ care, and absorbing the cognitive overhead of family life. The conditions for accumulating chronic stress are denser. The conditions for falling through cracks in the healthcare system are denser.

None of this is the disorder itself. It is the social geometry that surrounds the disorder. The mortality gap is, in this reading, a measurement of how badly that geometry serves women with ADHD specifically.

What the Study Does Not Say

Several misreadings of the research are predictable. They are worth pre-empting.

The study does not say that an ADHD diagnosis is a death sentence. The headline numbers are population averages. Within any population, there is enormous individual variation. A person with ADHD who has stable mental health, good access to care, supportive relationships, and the resources to navigate their condition is not facing the average mortality risk. The risk is concentrated in the population whose ADHD has been compounded by the cluster of adversities the study documents. Individuals are not their populations.

The study does not say that ADHD medications shorten or lengthen life. The mortality data the researchers analyzed cannot speak to this question. Other studies have looked specifically at the relationship between stimulant treatment and long-term outcomes, with mixed and complicated findings, but the O’Nions study is not one of them. Readers should not draw conclusions about medication from this paper.

The study does not say that adults with ADHD should panic. The opposite, in fact. The researchers’ framing is explicitly that the gap is modifiable, that it reflects unmet needs rather than an inevitable trajectory, and that the policy and clinical implications are about closing the gap, not about resigning to it.

The study also does not say that ADHD itself is more dangerous than was previously understood. The disorder is what it was before the study was published. What is newly visible is the long-term cost of how the disorder is currently being managed at the population level. The danger is not in the brain. It is in the system around it.

What Closing the Gap Would Look Like

If the mortality gap is produced by the cumulative effects of inadequate care, social adversity, and untreated comorbidities, the implications for what might close it are largely practical.

First, adequate identification matters. Adults with ADHD who are diagnosed earlier have a different trajectory than adults who go undiagnosed for decades. The decades of misattributed struggle, mental health comorbidities, and social adversity accumulate during the years a person does not know what is making their life harder. Closing the diagnostic gap, particularly for women and for adults whose ADHD was missed in childhood, is one of the most concrete interventions available.

Second, integrated mental health care matters. The comorbidities that contribute to mortality, depression, anxiety, substance use disorders, do not respond well to siloed treatment. A person with ADHD plus depression plus a substance use disorder needs care that addresses all three together. The fragmented nature of current healthcare systems, where different conditions are treated by different providers with limited communication, is particularly costly for patients with co-occurring conditions.

Third, healthcare access designed for ADHD matters. Scheduling appointments, refilling prescriptions, navigating insurance, following up on referrals, all of these require executive function. Healthcare systems that make these tasks easier, through reminders, simplified workflows, integrated care coordination, and respect for the cognitive demands they place on patients, will produce better outcomes for ADHD populations. Healthcare systems that make them harder will produce worse outcomes.

Fourth, social and economic support matters. The chronic stress of unstable employment, financial hardship, and relationship instability is a measurable contributor to long-term mortality. Adults with ADHD are overrepresented in each of these categories not because of any inevitable feature of the disorder but because the economic and social systems they navigate were not built for them. Policies that reduce these stressors, workplace accommodations, disability protections, accessible mental health care, will reduce the mortality differential.

Fifth, the framing of ADHD itself matters. The cultural conception of ADHD as a childhood disorder that adults are expected to have outgrown, or as a moral failing that adults are expected to manage through effort, produces real harm. Adults who internalize these framings are less likely to seek diagnosis, less likely to disclose their condition, and less likely to ask for the accommodations that would protect them. The neuroaffirming reframing, in which ADHD is understood as a difference in cognition rather than a deficit of character, removes one of the obstacles to the care that closes the gap.

What This Means for Readers

For adults with ADHD reading this article, the most important practical takeaways are concrete rather than abstract. The data describes a population average and is shaped by the conditions of life in that population. Individual outcomes are not destinies. The factors that drive the average mortality gap, untreated mental health comorbidities, inconsistent healthcare access, social isolation, chronic financial stress, are also the factors that can be addressed at the individual level with the right support.

The most actionable items are not surprising. Consistent mental health care, particularly attention to co-occurring depression, anxiety, and substance use, is among the highest-leverage interventions. A primary care relationship with a clinician who understands ADHD and is willing to work around the executive function demands of the healthcare system itself matters more than most patients realize. Treatment for ADHD itself, where appropriate and accessible, is associated with better long-term outcomes in many studies, though not all. Routine physical health maintenance, the things everyone is told to do but that are particularly hard with ADHD, are exactly the things the data identifies as protective.

For family members and partners of adults with ADHD, the article points toward the importance of supportive infrastructure. The cognitive overhead of healthcare, finances, and household management is a real burden, and it is a burden that compounds over decades. The people whose ADHD outcomes are best tend to be the people with strong relationships and social support. The people whose outcomes are worst tend to be the people who are alone with the cognitive load.

For clinicians, the article is a call to take adult ADHD seriously as a chronic health condition with measurable mortality implications, and to take the comorbidities seriously as part of the same care picture rather than as separate issues. A primary care visit with an adult with ADHD is an opportunity to address several risk factors at once. The opportunity is most often missed.

For policymakers and healthcare administrators, the article is an argument that the structural features of healthcare access are not neutral. The same system that delivers adequate care to neurotypical patients can systematically fail patients whose executive function is impaired. Closing the ADHD mortality gap is, in part, a question of redesigning the systems that surround the disorder to be navigable by the people who have it.

The Larger Frame

The O’Nions and Barkley findings, read together, point to a particular kind of public health failure. It is not the failure to identify a new disease. It is not the failure of medications to work, or of research to make progress. It is the failure to integrate a body of knowledge about a common condition into the actual practical conditions of care.

ADHD is one of the most studied conditions in pediatric psychiatry. Adult ADHD is increasingly well-characterized. The treatments work. The diagnostic criteria are clear. What has not happened is the translation of this knowledge into healthcare systems that are usable by the adults who have the condition, into social systems that accommodate rather than punish the cognitive differences the condition involves, and into public framings that allow adults to ask for help without shame.

The mortality gap is the long-term measurement of that translation failure. The good news, such as it is, is that translation failures are addressable. They require attention, resources, and the political will to design systems for the people who actually use them rather than for an idealized neurotypical patient who navigates healthcare and life without difficulty. The findings of the O’Nions study are not, in this reading, a tragedy. They are an argument for change.

The Study at a Glance